{"id":18567,"date":"2026-02-13T18:04:07","date_gmt":"2026-02-13T17:04:07","guid":{"rendered":"https:\/\/www.cbd.fr\/blog\/?p=18567"},"modified":"2026-02-13T18:04:08","modified_gmt":"2026-02-13T17:04:08","slug":"cbd-and-social-security-coverage-in-question","status":"publish","type":"post","link":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/","title":{"rendered":"CBD and social security: coverage in question"},"content":{"rendered":"<p>Cannabidiol, more commonly known as CBD, is a compound found in cannabis that is generating increasing interest for its therapeutic properties. Unlike <a href=\"https:\/\/www.cbd.fr\/198thccbd\" data-internallinksmanager029f6b8e52c=\"17\" title=\"thc - t\u00e9trahydrocannabinol\">THC<\/a>, another major component of cannabis, CBD has no psychoactive effects and does not produce a &#8220;high.&#8221; This makes it an attractive option for those seeking to enjoy its benefits without experiencing the adverse effects associated with cannabis use. <strong><\/strong>However, a question arises for patients wishing to use CBD as an alternative treatment: is this alternative medicine covered by social security? To answer this, it is necessary to examine several aspects, such as the current state of CBD legislation in France and the conditions for reimbursement of medical treatments.<\/p>\n<p>CBD Legislation in France<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_80 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Sommaire<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #43b981;color:#43b981\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #43b981;color:#43b981\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#Laws_governing_cannabis_products_vary_considerably_from_one_country_to_another_According_to_French_law_the_cultivation_possession_distribution_and_use_of_certain_varieties_of_hemp_plants_are_permitted_provided_they_contain_less_than_02_THC_However_this_low_THC_level_in_authorized_hemp_plants_does_not_necessarily_mean_that_CBD_products_can_be_sold_freely_if_they_exceed_the_maximum_permitted_THC_level\" >Laws governing cannabis products vary considerably from one country to another. According to French law, the cultivation, possession, distribution, and use of certain varieties of hemp plants are permitted provided they contain less than 0.2% THC. However, this low THC level in authorized hemp plants does not necessarily mean that CBD products can be sold freely if they exceed the maximum permitted THC level.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#CBD_in_Medicine\" >CBD in Medicine<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#For_a_treatment_to_be_covered_by_health_insurance_it_must_meet_several_criteria_it_must_have_received_marketing_authorization_be_listed_on_the_list_of_reimbursable_medications_and_comply_with_certain_conditions_set_by_the_French_National_Authority_for_Health_HAS\" >For a treatment to be covered by health insurance, it must meet several criteria: it must have received marketing authorization, be listed on the list of reimbursable medications, and comply with certain conditions set by the French National Authority for Health (HAS).<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#Regarding_the_CBD-based_medications_mentioned_earlier_Epidiolex_set_a_precedent_by_being_the_first_CBD-containing_medication_to_be_reimbursed_by_the_French_national_health_insurance_system_The_reimbursement_rate_is_set_at_65_for_this_medication_but_it_should_be_noted_that_its_prescription_is_strictly_limited_to_cases_of_severe_epilepsy_in_children_and_young_adults_As_for_Sativex_despite_its_marketing_authorization_it_is_still_not_available_in_France_due_to_a_disagreement_between_the_manufacturing_laboratory_and_the_Transparency_Commission_regarding_pricing_and_reimbursement\" >Regarding the CBD-based medications mentioned earlier, Epidiolex set a precedent by being the first CBD-containing medication to be reimbursed by the French national health insurance system. The reimbursement rate is set at 65% for this medication, but it should be noted that its prescription is strictly limited to cases of severe epilepsy in children and young adults. As for Sativex, despite its marketing authorization, it is still not available in France due to a disagreement between the manufacturing laboratory and the Transparency Commission regarding pricing and reimbursement.<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#CBD_Food_Supplements_and_Oils\" >CBD Food Supplements and Oils<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Laws_governing_cannabis_products_vary_considerably_from_one_country_to_another_According_to_French_law_the_cultivation_possession_distribution_and_use_of_certain_varieties_of_hemp_plants_are_permitted_provided_they_contain_less_than_02_THC_However_this_low_THC_level_in_authorized_hemp_plants_does_not_necessarily_mean_that_CBD_products_can_be_sold_freely_if_they_exceed_the_maximum_permitted_THC_level\"><\/span>Laws governing cannabis products vary considerably from one country to another. According to French law, the cultivation, possession, distribution, and use of certain varieties of hemp plants are permitted provided they contain less than 0.2% THC. However, this low THC level in authorized hemp plants does not necessarily mean that CBD products can be sold freely if they exceed the maximum permitted THC level.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<\/p>\n<p>On the other hand, CBD itself is not classified as a narcotic and is subject to a separate legal framework in France. CBD products are not subject to any specific regulations, but the authorities closely monitor the marketing of products containing cannabidiol to prevent any encouragement of cannabis use.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"CBD_in_Medicine\"><\/span>CBD in Medicine<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>From a medical standpoint, CBD has been studied for its analgesic, anti-inflammatory, neuroprotective, and anxiolytic properties. Some research suggests that this compound could be useful in treating numerous conditions, including:<\/p>\n<ul>\n<li>Chronic pain<\/li>\n<li>Fibromyalgia<\/li>\n<li>Epilepsy<\/li>\n<li>Anxiety and stress<\/li>\n<li>Depression<\/li>\n<li>Sleep disorders<\/li>\n<li>Inflammatory bowel disease<\/li>\n<li>Multiple sclerosis<\/li>\n<\/ul>\n<p>While some countries, such as the United States and Canada, have already legalized the use of medical cannabis, including for CBD prescriptions, France is only at the very beginning of this process. In 2020, the French National Agency for Medicines and Health Products Safety (ANSM) established a temporary specialized scientific committee tasked with evaluating the relevance and feasibility of using cannabis for therapeutic purposes. <\/p>\n<h3><\/h3>\n<p>CBD as a medicine: Epidiolex and Sativex<\/p>\n<p>However, there are already several CBD-containing medications that have received marketing authorization (MA) in France. Epidiolex, a medication prescribed for the treatment of certain severe forms of epilepsy, was the first CBD-based medication to obtain this MA.<\/p>\n<h2><\/h2>\n<p>Similarly, Sativex is another medication that contains both THC and CBD. It is used to treat patients with multiple sclerosis who suffer from severe muscle stiffness. Sativex is only available by prescription and under very strict conditions. Health insurance coverage for CBD: where do we stand?<\/p>\n<h3><span class=\"ez-toc-section\" id=\"For_a_treatment_to_be_covered_by_health_insurance_it_must_meet_several_criteria_it_must_have_received_marketing_authorization_be_listed_on_the_list_of_reimbursable_medications_and_comply_with_certain_conditions_set_by_the_French_National_Authority_for_Health_HAS\"><\/span>For a treatment to be covered by health insurance, it must meet several criteria: it must have received marketing authorization, be listed on the list of reimbursable medications, and comply with certain conditions set by the French National Authority for Health (HAS).<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>CBD-based medications and their reimbursement<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Regarding_the_CBD-based_medications_mentioned_earlier_Epidiolex_set_a_precedent_by_being_the_first_CBD-containing_medication_to_be_reimbursed_by_the_French_national_health_insurance_system_The_reimbursement_rate_is_set_at_65_for_this_medication_but_it_should_be_noted_that_its_prescription_is_strictly_limited_to_cases_of_severe_epilepsy_in_children_and_young_adults_As_for_Sativex_despite_its_marketing_authorization_it_is_still_not_available_in_France_due_to_a_disagreement_between_the_manufacturing_laboratory_and_the_Transparency_Commission_regarding_pricing_and_reimbursement\"><\/span>Regarding the CBD-based medications mentioned earlier, Epidiolex set a precedent by being the first CBD-containing medication to be reimbursed by the French national health insurance system. The reimbursement rate is set at 65% for this medication, but it should be noted that its prescription is strictly limited to cases of severe epilepsy in children and young adults. As for Sativex, despite its marketing authorization, it is still not available in France due to a disagreement between the manufacturing laboratory and the Transparency Commission regarding pricing and reimbursement.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<\/p>\n<h2><span class=\"ez-toc-section\" id=\"CBD_Food_Supplements_and_Oils\"><\/span>CBD Food Supplements and Oils<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Regarding food supplements and other formulas containing CBD, their coverage by the national health insurance system is much more uncertain. Generally, these products are not considered medications and therefore do not meet the criteria for reimbursement. However, given the rapid evolution of the cannabidiol market and its legal framework, it remains to be seen whether this situation could change in the future with new regulations. Preliminary Conclusion<\/p>\n\n\n<div class=\"kk-star-ratings kksr-auto kksr-align-left kksr-valign-bottom\"\n    data-payload='{&quot;align&quot;:&quot;left&quot;,&quot;id&quot;:&quot;18567&quot;,&quot;slug&quot;:&quot;default&quot;,&quot;valign&quot;:&quot;bottom&quot;,&quot;ignore&quot;:&quot;&quot;,&quot;reference&quot;:&quot;auto&quot;,&quot;class&quot;:&quot;&quot;,&quot;count&quot;:&quot;0&quot;,&quot;legendonly&quot;:&quot;&quot;,&quot;readonly&quot;:&quot;&quot;,&quot;score&quot;:&quot;0&quot;,&quot;starsonly&quot;:&quot;&quot;,&quot;best&quot;:&quot;5&quot;,&quot;gap&quot;:&quot;5&quot;,&quot;greet&quot;:&quot;Notez cet article&quot;,&quot;legend&quot;:&quot;0\\\/5 - (0 vote)&quot;,&quot;size&quot;:&quot;24&quot;,&quot;title&quot;:&quot;CBD and social security: coverage in question&quot;,&quot;width&quot;:&quot;0&quot;,&quot;_legend&quot;:&quot;{score}\\\/{best} - ({count} {votes})&quot;,&quot;font_factor&quot;:&quot;1.25&quot;}'>\n            \n<div class=\"kksr-stars\">\n    \n<div class=\"kksr-stars-inactive\">\n            <div class=\"kksr-star\" data-star=\"1\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" data-star=\"2\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" data-star=\"3\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" data-star=\"4\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" data-star=\"5\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n    <\/div>\n    \n<div class=\"kksr-stars-active\" style=\"width: 0px;\">\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n                \n\n<div class=\"kksr-legend\" style=\"font-size: 19.2px;\">\n            <span class=\"kksr-muted\">Notez cet article<\/span>\n    <\/div>\n    <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cannabidiol, more commonly known as CBD, is a compound found in cannabis that is generating increasing interest for its therapeutic properties. Unlike THC, another major component of cannabis, CBD has no psychoactive effects and does not produce a &#8220;high.&#8221; This makes it an attractive option for those seeking to enjoy its benefits without experiencing the [&hellip;]<\/p>\n","protected":false},"author":90,"featured_media":11649,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[923],"tags":[],"class_list":["post-18567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-faq-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.9 (Yoast SEO v26.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CBD and social security: coverage in question - CBD Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ud83c\udf31CBD and social security: coverage in question - CBD.fr \ud83c\udf31\" \/>\n<meta property=\"og:description\" content=\"Cannabidiol, more commonly known as CBD, is a compound found in cannabis that is generating increasing interest for its therapeutic properties. Unlike THC, another major component of cannabis, CBD has no psychoactive effects and does not produce a &#8220;high.&#8221; This makes it an attractive option for those seeking to enjoy its benefits without experiencing the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/\" \/>\n<meta property=\"og:site_name\" content=\"CBD Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cbdfrr\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T17:04:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-13T17:04:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2024\/01\/le-cbd-et-la-securite-sociale-une-prise-en-charge-en-question.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1456\" \/>\n\t<meta property=\"og:image:height\" content=\"832\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Julien\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Julien\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CBD and social security: coverage in question - CBD Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/","og_locale":"fr_FR","og_type":"article","og_title":"\ud83c\udf31CBD and social security: coverage in question - CBD.fr \ud83c\udf31","og_description":"Cannabidiol, more commonly known as CBD, is a compound found in cannabis that is generating increasing interest for its therapeutic properties. Unlike THC, another major component of cannabis, CBD has no psychoactive effects and does not produce a &#8220;high.&#8221; This makes it an attractive option for those seeking to enjoy its benefits without experiencing the [&hellip;]","og_url":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/","og_site_name":"CBD Blog","article_publisher":"https:\/\/www.facebook.com\/cbdfrr\/","article_published_time":"2026-02-13T17:04:07+00:00","article_modified_time":"2026-02-13T17:04:08+00:00","og_image":[{"width":1456,"height":832,"url":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2024\/01\/le-cbd-et-la-securite-sociale-une-prise-en-charge-en-question.jpg","type":"image\/jpeg"}],"author":"Julien","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Julien","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#article","isPartOf":{"@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/"},"author":{"name":"Julien","@id":"https:\/\/www.cbd.fr\/blog\/#\/schema\/person\/d78b472d184ec8ae4135d454e3338c04"},"headline":"CBD and social security: coverage in question","datePublished":"2026-02-13T17:04:07+00:00","dateModified":"2026-02-13T17:04:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/"},"wordCount":640,"publisher":{"@id":"https:\/\/www.cbd.fr\/blog\/#organization"},"image":{"@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2024\/01\/le-cbd-et-la-securite-sociale-une-prise-en-charge-en-question.jpg","articleSection":["Frequently asked questions"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/","url":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/","name":"CBD and social security: coverage in question - CBD Blog","isPartOf":{"@id":"https:\/\/www.cbd.fr\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#primaryimage"},"image":{"@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2024\/01\/le-cbd-et-la-securite-sociale-une-prise-en-charge-en-question.jpg","datePublished":"2026-02-13T17:04:07+00:00","dateModified":"2026-02-13T17:04:08+00:00","breadcrumb":{"@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#primaryimage","url":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2024\/01\/le-cbd-et-la-securite-sociale-une-prise-en-charge-en-question.jpg","contentUrl":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2024\/01\/le-cbd-et-la-securite-sociale-une-prise-en-charge-en-question.jpg","width":1456,"height":832,"caption":"Le CBD et la s\u00e9curit\u00e9 sociale : une prise en charge en question"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cbd.fr\/blog\/en\/cbd-and-social-security-coverage-in-question\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"CBD Blog","item":"https:\/\/www.cbd.fr\/blog\/"},{"@type":"ListItem","position":2,"name":"Frequently asked questions","item":"https:\/\/www.cbd.fr\/blog\/en\/category\/faq-en\/"},{"@type":"ListItem","position":3,"name":"CBD and social security: coverage in question"}]},{"@type":"WebSite","@id":"https:\/\/www.cbd.fr\/blog\/#website","url":"https:\/\/www.cbd.fr\/blog\/","name":"CBD Blog","description":"Le meilleur blog de CBD et du chanvre en France par CBD.fr","publisher":{"@id":"https:\/\/www.cbd.fr\/blog\/#organization"},"alternateName":"CBD.fr","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cbd.fr\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.cbd.fr\/blog\/#organization","name":"CBD.fr","alternateName":"CBD.fr","url":"https:\/\/www.cbd.fr\/blog\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cbd.fr\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2023\/01\/logo-cbd.png","contentUrl":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2023\/01\/logo-cbd.png","width":215,"height":100,"caption":"CBD.fr"},"image":{"@id":"https:\/\/www.cbd.fr\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cbdfrr\/","https:\/\/www.instagram.com\/cbdfr\/","https:\/\/www.youtube.com\/@CBD_fr","https:\/\/www.linkedin.com\/company\/cbd-fr\/"],"description":"CBD.fr est le leaders fran\u00e7ais du bien-\u00eatre et du CBD, proposant une large gamme de produits \u00e0 base de chanvre rigoureusement s\u00e9lectionn\u00e9s. Expertise, qualit\u00e9 et p\u00e9dagogie sont au c\u0153ur de l\u2019exp\u00e9rience CBD.fr.","email":"support@cbd.fr","telephone":"0189720196","legalName":"CBD.fr","foundingDate":"2021-01-01","taxID":"760933","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"11","maxValue":"50"}},{"@type":"Person","@id":"https:\/\/www.cbd.fr\/blog\/#\/schema\/person\/d78b472d184ec8ae4135d454e3338c04","name":"Julien","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cbd.fr\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/58f2f1b1e71c329d0226efe2cc40174640e1757e077dac013c980f3ee43c73a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/58f2f1b1e71c329d0226efe2cc40174640e1757e077dac013c980f3ee43c73a0?s=96&d=mm&r=g","caption":"Julien"},"description":"R\u00e9dacteur en chef sp\u00e9cialis\u00e9 en CBD Julien, n\u00e9 le 17 juillet 1978 en r\u00e9gion Parisienne, est un \u00e9minent r\u00e9dacteur et expert dans le domaine des produits \u00e0 base de CBD. Suite \u00e0 ses \u00e9tudes, Julien a d\u00e9velopp\u00e9 une passion pour les rem\u00e8des naturels, dont le CBD. En 2022, il int\u00e8gre l\u2019\u00e9quipe du site CBD.fr en qualit\u00e9 d\u2019expert et de contributeur r\u00e9gulier. Gr\u00e2ce \u00e0 son expertise scientifique et une \u00e9criture claire, Julien aide \u00e0 d\u00e9mystifier les aspects complexes du CBD, tout en mettant en lumi\u00e8re ses bienfaits et applications potentielles \u00e0 travers ses articles et participations \u00e0 des conf\u00e9rences.","honorificPrefix":"Mr","gender":"male","knowsAbout":["CBD","Cannabis","Copywriter"],"knowsLanguage":["French"],"jobTitle":"Editor-in-chief specializing in CBD","worksFor":"CBD.fr","url":"https:\/\/www.cbd.fr\/blog\/author\/redac-cbd\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/posts\/18567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/users\/90"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/comments?post=18567"}],"version-history":[{"count":1,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/posts\/18567\/revisions"}],"predecessor-version":[{"id":18568,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/posts\/18567\/revisions\/18568"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/media\/11649"}],"wp:attachment":[{"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/media?parent=18567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/categories?post=18567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/tags?post=18567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}